Multimodality vaccination against clade C SHIV: partial protection against mucosal challenges with a heterologous tier 2 virus.

PubWeight™: 0.81‹?›

🔗 View Article (PMC 4343195)

Published in Vaccine on September 20, 2014

Authors

Samir K Lakhashe1, Siddappa N Byrareddy2, Mingkui Zhou1, Barbara C Bachler3, Girish Hemashettar3, Shiu-Lok Hu4, Francois Villinger5, James G Else5, Shannon Stock3, Sandra J Lee6, Diego A Vargas-Inchaustegui7, Egidio Brocca Cofano7, Marjorie Robert-Guroff7, Welkin E Johnson8, Victoria R Polonis9, Donald N Forthal10, Erwann P Loret11, Robert A Rasmussen6, Ruth M Ruprecht12

Author Affiliations

1: Texas Biomedical Research Institute, San Antonio, TX, USA; Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
2: Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.
3: Dana-Farber Cancer Institute, Boston, MA, USA.
4: University of Washington, Seattle, WA, USA.
5: Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA; Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
6: Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
7: Vaccine Branch, National Cancer Institute, National Institute of Health, Bethesda, MD, USA.
8: Biology Department, Boston College, MA, USA.
9: The Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
10: Division of Infectious Diseases, Department of Medicine, University of California, Irvine School of Medicine, Irvine, CA, USA.
11: ETRAV Laboratory, Faculty of Pharmacy, Aix Marseille University/CNRS, 27 BD Jean Moulin, 13385 Marseille Cedex 5, France.
12: Texas Biomedical Research Institute, San Antonio, TX, USA; Southwest National Primate Research Center, San Antonio, TX, USA; Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: rruprecht@txbiomed.org.

Articles cited by this

Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med (2011) 69.36

Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res (2003) 52.74

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science (2010) 35.19

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62

Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med (2012) 12.98

Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature (2011) 9.30

Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol (2009) 5.91

Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. J Med Primatol (2005) 5.76

Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol (2006) 5.25

Correlates of protection induced by vaccination. Clin Vaccine Immunol (2010) 5.21

HIV prevention transformed: the new prevention research agenda. Lancet (2011) 4.23

DNA vaccines: ready for prime time? Nat Rev Genet (2008) 4.10

Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3). J Virol (2001) 3.20

Immune clearance of highly pathogenic SIV infection. Nature (2013) 3.15

Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys. Sci Transl Med (2011) 3.08

Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis (2012) 2.89

Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity (2011) 2.82

Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol (2005) 2.72

Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC. Virology (2010) 2.61

Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge. J Virol (2009) 2.38

Sensitive and robust one-tube real-time reverse transcriptase-polymerase chain reaction to quantify SIV RNA load: comparison of one- versus two-enzyme systems. AIDS Res Hum Retroviruses (2000) 2.37

Network structures and algorithms in Bioconductor. Bioinformatics (2004) 2.04

Molecularly cloned SHIV-1157ipd3N4: a highly replication- competent, mucosally transmissible R5 simian-human immunodeficiency virus encoding HIV clade C Env. J Virol (2006) 1.87

Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines. Nat Med (2012) 1.86

Vaccine-induced CD8+ T cells control AIDS virus replication. Nature (2012) 1.78

Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine. J Infect Dis (2011) 1.76

Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells. J Virol (2006) 1.76

Portable flanking sequences modulate CTL epitope processing. J Clin Invest (2007) 1.72

Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques. J Virol (1999) 1.60

Male circumcision for HIV prevention: current evidence and implementation in sub-Saharan Africa. J Int AIDS Soc (2011) 1.42

A highly defective HIV-1 strain isolated from a healthy Gabonese individual presenting an atypical western blot. AIDS (1989) 1.40

Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies. J Virol (2011) 1.33

R5 clade C SHIV strains with tier 1 or 2 neutralization sensitivity: tools to dissect env evolution and to develop AIDS vaccines in primate models. PLoS One (2010) 1.29

Monocyte chemotactic protein-2 activates CCR5 and blocks CD4/CCR5-mediated HIV-1 entry/replication. J Biol Chem (1998) 1.26

Lessons learned from HIV-1 vaccine trials: new priorities and directions. Nat Immunol (2012) 1.23

Characterization of a simian human immunodeficiency virus encoding the envelope gene from the CCR5-tropic HIV-1 Ba-L. J Acquir Immune Defic Syndr (2003) 1.21

Neutralization-sensitive R5-tropic simian-human immunodeficiency virus SHIV-2873Nip, which carries env isolated from an infant with a recent HIV clade C infection. J Virol (2008) 1.14

Pathogenicity and mucosal transmissibility of the R5-tropic simian/human immunodeficiency virus SHIV(AD8) in rhesus macaques: implications for use in vaccine studies. J Virol (2012) 1.14

Infectious molecular clone of a recently transmitted pediatric human immunodeficiency virus clade C isolate from Africa: evidence of intraclade recombination. J Virol (2004) 1.13

Control of viremia and prevention of AIDS following immunotherapy of SIV-infected macaques with peptide-pulsed blood. PLoS Pathog (2008) 1.10

Efficacy of a multigenic protein vaccine containing multimeric HIV gp160 against heterologous SHIV clade C challenges. AIDS (2007) 1.08

Full peptide synthesis, purification, and characterization of six Tat variants. Differences observed between HIV-1 isolates from Africa and other continents. J Biol Chem (1999) 1.03

Enhanced cellular immunity in macaques following a novel peptide immunotherapy. J Virol (2005) 1.02

Variable HIV peptide stability in human cytosol is critical to epitope presentation and immune escape. J Clin Invest (2011) 1.02

Novel biopanning strategy to identify epitopes associated with vaccine protection. J Virol (2013) 1.01

Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges. Vaccine (2011) 1.01

Tat HIV-1 primary and tertiary structures critical to immune response against non-homologous variants. J Biol Chem (2002) 1.00

Induction of CD8+ regulatory T cells protects macaques against SIV challenge. Cell Rep (2012) 0.99

Vaccination against heterologous R5 clade C SHIV: prevention of infection and correlates of protection. PLoS One (2011) 0.98

Reservoir cells no longer detectable after a heterologous SHIV challenge with the synthetic HIV-1 Tat Oyi vaccine. Retrovirology (2006) 0.90

cn.FARMS: a latent variable model to detect copy number variations in microarray data with a low false discovery rate. Nucleic Acids Res (2011) 0.89

Promiscuous binding of extracellular peptides to cell surface class I MHC protein. Proc Natl Acad Sci U S A (2012) 0.88

Safety, immunogenicity and efficacy of peptide-pulsed cellular immunotherapy in macaques. J Med Primatol (2008) 0.88

No acquisition: a new ambition for HIV vaccine development? Curr Opin Virol (2011) 0.87

Sequential immunizations with rgp120s from independent isolates of human immunodeficiency virus type 1 induce the preferential expansion of broadly crossreactive B cells. J Exp Med (1991) 0.85

Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose. Retrovirology (2014) 0.85

Bimodal AIDS vaccine approach: induction of cellular as well as humoral immunity can protect from systemic infection. Vaccine (2010) 0.83

Overlapping synthetic peptides as vaccines. Vaccine (2006) 0.83

Overlapping synthetic peptides encoding TPD52 as breast cancer vaccine in mice: prolonged survival. Vaccine (2009) 0.81

Mucosal transmissibility, disease induction and coreceptor switching of R5 SHIVSF162P3N molecular clones in rhesus macaques. Retrovirology (2013) 0.80

Intradermal vaccination of HIV-infected patients with short HIV Gag p24-like peptides induces CD4 + and CD8 + T cell responses lasting more than seven years. Scand J Infect Dis (2012) 0.80

Identification of a highly conserved surface on Tat variants. J Biol Chem (2013) 0.80

Live-virus exposure of vaccine-protected macaques alters the anti-HIV-1 antibody repertoire in the absence of viremia. Retrovirology (2013) 0.76